BCX7353

Unassigned

New Medicines

Hereditary angioedema (HAE) type I and II – for prevention of acute attacks

Information

New molecular entity
BioCryst Pharmaceuticals
BioCryst Pharmaceuticals

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes

Category

Small-molecule human plasma kallikrein inhibitor which inhibits isolated human plasma kallikrein activity
HAE affects 1 in 50,000 to 100,000 people of any ethnic group and of either gender. According to the UK population mid-year estimate 2016, there are 65,648,100 people in the UK [1].
Hereditary angioedema (HAE) type I and II – for prevention of acute attacks
Oral